Sally Shorthose is one of our leading intellectual property (IP) partners. She provides a full range of intellectual property commercial advice and support to her clients, including licensing, partnering and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and 'freedom to operate' matters, and manages significant due diligence matters. As a transactional intellectual property lawyer, Sally provides advice in relation to the protection and exploitation of a full range of IP rights, both in stand alone transactions and as part of an acquisition, divestment or investment activity.
Before joining us in 2006, Sally was head of IP and Life Sciences at Eversheds, and prior to that she spent 11 years working in-house firstly as senior legal advisor at ICI/Zeneca and latterly as Legal Director of Novartis UK. This in-house experience gave her significant insight into the need to give pragmatic and commercial advice.
Sally's recent work includes acting for Isentropic, who are entering a major development agreement relating to a novel energy storage and distribution technology; Waste2Energy, a producer of state-of-the-art gasifiers which produce syngas from waste, on their patent portfolio and a number of passing off issues; and Ceravision, a private UK-based company leading the world through the development of High Efficiency Plasma (HEP) technology.
Sally is a regular speaker at conferences and seminars on a range of IP related subjects, particularly in relation to regulatory, licensing and exploitation matters. She is the author of the recent publication "The EU Guide to Pharmaceutical Regulatory Law".
Recently, Sally was one of eight pharmaceutical licensing experts drawn from around the world to work together with representatives from UNITAID and WIPO at a workshop to determine the licensing provisions for the supply of drugs to third world countries.